Nanjing Drum Tower Hospital

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Intraoperative Ultrasound Assessment of Coronary Artery and Bypass Graft Blood Flow During CABG

  NCT07700524· The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School· Source

• Not yet recruiting

  A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

  NCT07789015· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC

  NCT07720193· Phase 3· Nanjing Leads Biolabs Co.,Ltd· Source

• Recruiting

  Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure

  NCT07575672· Phase 3· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Not yet recruiting

  Real-world Study of the Effectiveness and Tolerability of Outpatient Titration of OxyContin for the Moderate and Severe Pain in Cancer Patients

  NCT07869797· Mundipharma (China) Pharmaceutical Co. Ltd· Source

• Recruiting

  Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)

  NCT07687459· Phase 3· InSilico Medicine Hong Kong Limited· Source

• Recruiting

  A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.

  NCT07653685· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Not yet recruiting

  Sphere-9 PAF China Study

  NCT07789925· Medtronic Cardiac Ablation Solutions· Source

• Not yet recruiting

  Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response

  NCT07797231· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Not yet recruiting

  Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases

  NCT07745257· Phase 2· Sun Yat-sen University· Source

• Recruiting

  A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity

  NCT07747857· Phase 1· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Not yet recruiting

  A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma

  NCT07741617· Phase 2· The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School· Source

• Recruiting

  A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy

  NCT07468851· Phase 1/2· Jiangsu Hansoh Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours

  NCT07533708· Phase 1· Shanghai Henlius Biotech· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects

  NCT07670884· Phase 3· Fujian Shengdi Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis

  NCT07406035· Phase 2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Recruiting

  Ruxolitinib Cream Combined With Corticosteroids for Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study

  NCT07673640· ShanShan Li· Source

• Recruiting

  A Study of Metformin to Improve Cardiac Function After LVAD Implantation

  NCT07666698· Phase 1/2· The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School· Source

• Recruiting

  A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis

  NCT07551427· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

  NCT07554339· Phase 3· Merck Sharp & Dohme LLC· Source

• Not yet recruiting

  Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy

  NCT07627464· Phase 2· Tianjin Medical University Cancer Institute and Hospital· Source

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Multicenter, RAndomIzed, coNtrolled, umBrella Trial fOr Minimally Invasive Neurosurgery With AI-assisted Robotic guidanCe for Hemorrhagic Stroke

  NCT06459427· Yanbing Yu· Source

• Recruiting

  A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions

  NCT07532538· The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School· Source

• Recruiting

  A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

  NCT07365995· Phase 3· BioNTech SE· Source

• Recruiting

  A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

  NCT07409181· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

  NCT07385703· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source

• Active, not recruiting

  A Study of SYH2082 Injection in Healthy Participants

  NCT07736404· Phase 1· CSPC Ouyi Pharmaceutical Co., Ltd.· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents

  NCT07472725· Phase 2· Jiangsu HengRui Medicine Co., Ltd.· Source

• Recruiting

  A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

  NCT07355218· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Recruiting

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection

  NCT07367529· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.

  NCT07396337· Phase 2· Changzhou Qianhong Bio-pharma Co., Ltd.· Source

• Recruiting

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study of SYH2069 Injection in Healthy Participants

  NCT07736391· Phase 1· CSPC Ouyi Pharmaceutical Co., Ltd.· Source

• Not yet recruiting

  Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

  NCT07328919· Phase 3· TransThera Sciences (Nanjing), Inc.· Source

• Recruiting

  Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer

  NCT07298200· Phase 1· Jia Wei· Source

• Recruiting

  A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07225946· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

  NCT07185997· Phase 3· ArriVent BioPharma, Inc.· Source

• Recruiting

  A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus

  NCT07323173· Phase 1· Nanjing Leads Biolabs Co.,Ltd· Source

• Recruiting

  A Phase II Trial of LM103 in Advanced Melanoma

  NCT07310784· Phase 2· Suzhou BlueHorse Therapeutics Co., Ltd.· Source

• Recruiting

  A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors

  NCT07179679· Phase 1· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

  NCT07230106· Phase 2· Jiangsu HengRui Medicine Co., Ltd.· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

  NCT06937229· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

  NCT07176650· Phase 1· Shanghai Henlius Biotech· Source

Showing 50 of 164.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer12 recruiting
• Prostate cancer9 recruiting
• Gastric and oesophageal cancer7 recruiting
• Multiple myeloma6 recruiting
• Lupus (SLE)5 recruiting
• Pancreatic cancer5 recruiting
• Alzheimer disease4 recruiting
• Bladder cancer4 recruiting
• Colorectal cancer4 recruiting
• Melanoma4 recruiting
• Metastatic breast cancer4 recruiting
• Obesity4 recruiting
• Fatty liver disease (MASLD/MASH)3 recruiting
• Head and neck cancer3 recruiting
• Heart failure3 recruiting
• Hepatitis B3 recruiting
• High blood pressure3 recruiting
• Liver and biliary tract cancer3 recruiting
• Type 2 diabetes3 recruiting
• Bronchiectasis2 recruiting
• Childhood cancers2 recruiting
• Endometrial cancer2 recruiting
• Immune thrombocytopenia (ITP)2 recruiting
• Kidney cancer2 recruiting
• Stroke2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Acute myeloid leukaemia1 recruiting
• Atrial fibrillation1 recruiting
• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Liver cirrhosis1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroendocrine tumours1 recruiting
• Ovarian cancer1 recruiting
• Peripheral artery disease1 recruiting
• Primary biliary cholangitis1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Triple-negative breast cancer1 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  a Salivary Cell-free RNA Liquid Biopsy Model for Non-invasive Diagnosis in Sjögren's Disease

  NCT07824440· The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School· Source

• Completed

  A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder

  NCT07252908· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

  NCT07217301· Phase 3· Takeda· Source

• Completed

  Efficacy and Safety of HRS9531 Tablet in Obese Subjects

  NCT06841445· Phase 2· Fujian Shengdi Pharmaceutical Co., Ltd.· Source

• Completed

  TGRX-678 Phase I Oral Pharmacokinetic Study

  NCT06697899· Phase 1· Shenzhen TargetRx Co., Ltd.· Source

• Completed

  Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

  NCT06670352· Phase 2· Haisco Pharmaceutical Group Co., Ltd.· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Boehringer Ingelheim· Source

• Completed

  HTA of NIVATS Based on RWE

  NCT06574295· Fudan University· Source

• Completed

  Observational Study of the Use of Extraneal in Peritoneal Dialysis in Patients

  NCT06492031· Vantive Health LLC· Source

• Completed

  An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China

  NCT06421740· AbbVie· Source

• Completed

  DNA Methylation Biomarkers to Predict Survival After Surgery for Lung Adenocarcinoma

  NCT06477211· Nanjing University· Source

• Completed

  RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

  NCT06173037· Phase 2· RemeGen Co., Ltd.· Source

• Completed

  A Clinical Study of JS005 in Patients With Ankylosing Spondylitis

  NCT06250062· Phase 2· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein

  NCT06142552· Phase 3· Hangzhou Gensciences Biopharmaceutical Co., Ltd.· Source

• Completed

  Assessment of Gastric Emptying by SHR20004 in Healthy Subjects

  NCT06137469· Phase 1· Jiangsu HengRui Medicine Co., Ltd.· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Terminated

  Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

  NCT06206278· Phase 2· LianBio LLC· Source

• Completed

  A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06049017· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

  NCT06068465· Phase 3· Tasly Pharmaceutical Group Co., Ltd· Source

• Completed

  Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery

  NCT07374445· Phase 4· The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School· Source

• Terminated

  A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis

  NCT05849727· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05938920· Phase 2· InSilico Medicine Hong Kong Limited· Source

• Completed

  Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

  NCT05814627· Phase 3· AbbVie· Source

• Completed

  A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects

  NCT05895565· Phase 1· Pulmongene Ltd.· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome

  NCT05673993· Phase 3· RemeGen Co., Ltd.· Source

• Completed

  Study to Assess PK, Safety and Tolerability in Healthy Subjects

  NCT06380699· Phase 1· Changzhou Qianhong Bio-pharma Co., Ltd.· Source

• Completed

  rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)

  NCT05700591· Phase 3· Tasly Biopharmaceuticals Co., Ltd.· Source

• Completed

  A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise

  NCT05628311· Phase 3· Innovent Biologics (Suzhou) Co. Ltd.· Source

• Completed

  A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients

  NCT05680155· Phase 3· Hangzhou Sciwind Biosciences Co., Ltd.· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Completed

  Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate

  NCT05590793· Phase 3· Ipsen· Source

• Completed

  A Study of IBI362 in Participants With Obesity or Overweight

  NCT05607680· Phase 3· Innovent Biologics (Suzhou) Co. Ltd.· Source

• Completed

  Clinical Trial in China for Aortic Valve Stenosis

  NCT05607667· Genesis Medtech Corporation· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  NCT05523167· Phase 2/3· argenx· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)

  NCT05394805· AbbVie· Source

• Completed

  A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma

  NCT05420324· Phase 2· Eucure (Beijing) Biopharma Co., Ltd· Source

• Completed

  To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

  NCT05253053· Phase 1/2· TransThera Sciences (Nanjing), Inc.· Source

• Completed

  Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes

  NCT07282054· Phase 3· Tonghua Dongbao Pharmaceutical Co.,Ltd· Source

• Completed

  Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation

  NCT04942834· Ruijin Hospital· Source

• Completed

  A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A

  NCT05092841· Phase 3· Tasly GeneNet Pharmaceuticals Co., Ltd· Source

• Completed

  Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

  NCT04934722· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

  NCT04662710· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

  NCT04509674· Phase 3· Boehringer Ingelheim· Source

• Completed

  Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC

  NCT04723004· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

  NCT04574284· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  Safety and Effectiveness of ENTERPRISE 2 Device in the Endovascular Treatment of Intracranial Aneurysms

  NCT04289480· Medos International SARL· Source

• Completed

  Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study

  NCT04889118· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Efficacy and Influencing Factors of Secukinumab in Patients With Axial Spondyloarthritis

  NCT07130331· The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School· Source

Showing 50 of 62.

Conditions

Diseases this institution publishes on or runs trials for.

• Liver and biliary tract cancer112 works · 6 trials
• Colorectal cancer69 works · 4 trials
• Gastric and oesophageal cancer65 works · 12 trials
• Pancreatic cancer38 works · 6 trials
• Lupus (SLE)37 works · 6 trials
• Osteoarthritis34 works · 0 trials
• Fatty liver disease (MASLD/MASH)34 works · 4 trials
• Bladder cancer31 works · 12 trials
• Osteoporosis28 works · 0 trials
• Hepatitis B24 works · 3 trials
• Hearing loss23 works · 0 trials
• Rheumatoid arthritis22 works · 2 trials
• Idiopathic pulmonary fibrosis19 works · 6 trials
• Aortic aneurysm18 works · 0 trials
• Ankylosing spondylitis16 works · 2 trials
• Sjögren's disease13 works · 2 trials
• Diffuse large B-cell lymphoma12 works · 1 trial
• Mantle cell lymphoma7 works · 0 trials
• Liver cirrhosis6 works · 1 trial
• Brain aneurysm6 works · 1 trial
• Gout5 works · 0 trials
• Trigeminal neuralgia3 works · 0 trials